Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Celgene Corporation (CELG), Accelerate Diagnostics Inc (AXDX) and Metabolix, Inc. (MBLX) Among Birchview’s Top Bioscience Picks

Dr. Matthew Strobeck‘s Birchview Capital has recently disclosed its equity holdings in a 13F filing with the SEC. The market value of the fund’s equity portfolio stood at $191.76 million at the end of the March quarter with a comparatively low turnover ratio of 12.82%.

Celgene Corporation (NASDAQ:CELG)

Dr. Matthew Strobeck received his doctorate degree from the University of Cincinnati in 2001. He founded the Biosciences-focused fund, Birchview Capital in 2014 and is currently its Chief Investment Officer & Limited Partner. Birchview invests primarily in healthcare and environment industries. Strobeck is also an Independent Director at Accelerate Diagnostics Inc (NASDAQ:AXDX), and Metabolix, Inc. (NASDAQ:MBLX). Previously, he was a Partner at Westfield Capital Management and also served as a consultant for Thomas Weisel Asset Management. Some of the top picks of the fund at the end of the first quarter were Celgene Corporation (NASDAQ:CELG), Vermillion, Inc. (NASDAQ:VRML), and EQT Corporation (NYSE:EQT).

Through our research at Insider Monkey, we have formulated a portfolio strategy based on 15 most popular small cap picks of hedge funds. Back tests ranging from 1991 to 2012 revealed that this strategy outperformed the market by nearly a percentage point per month, while the most popular large cap picks of hedge funds underperformed the market by 7 basis points per month during the same period. In forward tests since August 2012 through March 2015 our small cap strategy beat the market by a hefty 79.4 percentage points (read the details here). Hence a retail investor needs to isolate himself from the herd and take advantage of the prevalent arbitrage opportunities in the market by concentrating on small-caps

Birchview added 26,252 shares of Celgene Corporation (NASDAQ:CELG) in the first quarter to take the company’s holding to 840,163 shares valued at $96.86 million. The holding is by far the fund’s largest and amasses 50.51% of the  fund’s portfolio value. Among the billionaires that we track, five had an aggregate investment of $201.81 million in Celgene Corporation (NASDAQ:CELG) at the end of the fourth quarter. Ken Griffin was one of them as his fund, Citadel Investment Group, held about 924,600 shares valued at $103.43 million.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.